Adjuvant immunotherapy for melanoma and colorectal cancers

Seminars in Oncology

Volumn 28, Issue 1, 2001, Pages 68-92

  Safa, Malek M ^a   Foon, Kenneth A ^a  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DINITROPHENOL; BCG VACCINE; BISMUTH; CANCER VACCINE; CANCER VAX; CARBOHYDRATE; CARCINOEMBRYONIC ANTIGEN; CELL SURFACE PROTEIN; COLONY STIMULATING FACTOR 1; COPPER 67; EDRECOLOMAB; GANGLIOSIDE; GENE PRODUCT; HAPTEN; IMMUNOGLOBULIN G2A; IODINE 125; IODINE 131; LEUKOCYTE ANTIGEN; MELANOMA CELL VACCINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 3F8; MONOCLONAL ANTIBODY 47.8; MONOCLONAL ANTIBODY 96.5; MONOCLONAL ANTIBODY L6; MONOCLONAL ANTIBODY L72; MONOCLONAL ANTIBODY R24; MUCIN 1; PEPTIDE; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VACCINIA ONCOLYSATE; YTTRIUM 90;

ANTINEOPLASTIC ACTIVITY; CANCER DIAGNOSIS; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CELL LYSATE; CLINICAL TRIAL; COLORECTAL CANCER; DIAGNOSTIC ACCURACY; DRUG EFFICACY; DRUG TARGETING; GENE EXPRESSION REGULATION; GENE TRANSFER; GENETIC TRANSFECTION; HUMAN; IMMUNOTHERAPY; MELANOMA; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; REVIEW; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; VACCINATION;

EID: 0035119034     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(01)90046-6     Document Type: Article

References (250)

1. Cancer Statistics, 2000
2. Cancer of the colon
3. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: A final report
4. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: Results from National Surgical Adjuvant Breast and Bowel Project protocol C-03
5. Fluorouracil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer: Five-year final report of INT-0089
6. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: Seven-year outcome of a multicenter randomized trial
7. Cancer statistics
8. Adjuvant systemic therapy
9. Adjuvant interferon treatment for melanoma
10. Phase I trial of murine monoclonal antibody L6 in combination with subcutaneous interleukin-2 in patients with advanced carcinoma of the breast, colorectum, and lung
11. Phase II trial of murine monoclonal antibody D612 combined with recombinant human monocyte colony-stimulating factor (rhM-CSF) in patients with metastatic gastrointestinal cancer
12. Effect of monoclonal antibody 17-1A and GM-CSF in patients with advanced colorectal carcinoma - Long-lasting, complete remissions can be induced
13. The use of monoclonal antibody in a phase I clinical trial of human gastrointestinal tumors
14. Effects of monoclonal antibody immunotherapy on patients with gastrointestinal adenocarcinoma
15. Phase II clinical trial of a murine monoclonal antibody cytotoxic for gastroin-testinal adenocarcinoma
16. Antibody delivery and effector cell activation in a phase II trial of recombinant gamma-interferon and murine monoclonal antibody CD17-1A in advanced colorectal carcinoma
17. Tumor regression in monoclonal antibody-treated patients correlates with the presence of anti-idiotype-reactive T lymphocytes
18. Randomized trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma
19. Monoclonal mouse antibody raised against human lung carcinoma
20. Antitumor effects of L6, an IgG2a antibody that reacts with most human carcinomas
21. A monoclonal antibody (D612) with selective reactivity for malignant and normal gastrointestinal epithelium
22. Human lymphokine-activated killer cells augment immunotherapy of human colon carcinoma xenografts in monoclonal antibody D612
23. Macrophage colony-stimulating factor enhancement of antibody-dependent cellular cytotoxicity against human colon carcinoma cells
24. A phase I clinical trial of murine monoclonal antibody D612 in patients with metastatic gastrointestinal cancer
25. Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: Induction of inflammatory responses at tumor sites
26. Anti-melanoma effects of R24, a monoclonal antibody against GD3 ganglioside
27. A phase I study of anti-GD3 ganglioside monoclonal antibody R24 and recombinant human macrophage-colony stimulating factor in patients with metastatic melanoma
28. Ganglioside GD2 specific monoclonal antibody 3F8: A phase I study in patients with neuroblastoma and malignant melanoma
29. Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2
30. Pilot trial of murine monoclonal antibodies in patients with advanced melanoma
31. In-111-labeled monoclonal antibody immunoscintigraphy in colorectal carcinoma: Safety, sensitivity, and preliminary clinical resuits
32. Radiolabeled antibody imaging in the management of colorectal cancer. Results of a multicenter clinical study
33. Indium-111 monoclonal antibody B72.3 scintigraphy in colorectal cancer. Correlation with computed tomography, surgery, histopathology, immunohistology, and human immune response
34. 111In-labeled monoclonal antibody conjugate CYT-103
35. Clinical utility of external immunoscintigraphy with the IMMU-4 technetium-99m Fab' antibody fragment in patients undergoing surgery for carcinoma of the colon and rectum: Results of a pivotal, phase II trial
36. Antibody targeting in metastatic colon cancer: A phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts
37. Status of radiolabeled monoclonal antibodies for diagnosis and therapy of cancer
38. Radioimmuno-therapy: Recent results and future directions
39. Monoclonal antibodies in cancer detection and therapy
40. 131I-CC49 in colorectal cancer
41. Phase I trial of iodine-131-chimeric B72.3 (human IgG4) in metastatic colorectal cancer
42. Phase I/II study of iodine 131-labeled monodonal antibody A33 in patients with advanced colon cancer
43. Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer
44. 131I-labeled p97-specific Fab fragments in human melanoma as a basis for radiotherapy
45. Radioimmu-noimaging in malignant melanoma patients with the use of indium-111-labeled antimelanoma monodonal antibody (ZME-018) to high-molecular-weight antigen
46. Clinical use of a standard kit-preparation of radiolabeled monoclonal antibody 96.5 in the diagnostic imaging of metastatic melanoma
47. Radioimaging of melanoma using 99mTc-labeled Fab fragment reactive with a high molecular weight melanoma antigen
48. Bifunctional antibody: A binary radiopharmaceutical delivery system for imaging colorectal carcinoma
49. Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients
50. Mouse/human chimeric antibodies to a tumor-associated antigen: Biologic activity of the four human IgG subclasses
51. Replacing the complementarity-determining regions in a human antibody with those from the mouse
52. Reshaping antibodies for therapy
53. 131I-chimeric mouse/human B72.3 monoclonal antibody in humans
54. Vaccine trials for the clinician: Prospects for tumor antigens
55. The cell biology of antigen processing and presentation
56. Antigen processing. Transporters of delight
57. Antigen recognition by class I restricted T lymphocytes
58. A molecular model of MHC class-I-restricted antigen processing
59. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules
60. Consensus motifs and peptide ligands of MHC class I molecules
61. Helper activity is required for the in vitro generation of cytotoxic T lymphocytes
62. Helper T cells for cytotoxic T lymphocytes need not be region restricted
63. Cooperation between cytotoxic and helper T lymphocytes in protection against lethal Sendal virus infection
64. The dendritic cell system and its role in immunogenicity
65. Manipulation of co-stimulatory signals to enhance antitumor T-cell responses
66. T-cell mediated immune regulation: Help and suppression
67. MHC-restricted cytotoxic cell: Studies on the biological role of polymorphic major transplantation antigens determining T cell restriction-specificity, function and responsiveness
68. Presentation of exogenous antigen with class I major histocompatibility complex molecules
69. MHC class I-restricted presentation of exogenous antigen by thymic antigen-presenting cells in vitro and in vivo
70. Characterization of antigen-presenting cells that present exogenous antigens in association with class I MHC molecules
71. Phagocytic processing of exogenous particulate antigens by macrophages for presentation by class I MHC molecules
72. A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules
73. Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial
74. Active-specific immunotherapy of established micrometastases with BCG plus tumor cell vaccines: Effective treatment of BCG side effects with isoniazid
75. Therapy of spontaneous metastases with an autologous tumor vaccine in a guinea pig model
76. Mechanism of action of BCG-tumor cell vaccines in the generation of systemic tumor immunity. Synergism between BCG and line 10 tumor cells in the induction of an inflammatory response
77. Active-specific immunotherapy of established micrometastasis: Effect of cryopreservation procedures on tumor cell immunogenicity in guinea pigs
78. Preparation of immunotherapeutic autologous tumor cell vaccines from solid tumors
79. Newcastle disease virus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma
80. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group study E5283
81. Autoimmunization with irradiated tumor cells in human malignant melanoma
82. Clinical experience in the immunotherapy of cancer
83. Immunization with irradiated tumor cells and specific lymphocyte cytotoxicity in malignant melanoma
84. Immunotherapy of malignant melanoma. A clinical trial
85. Feasibility study of immunotherapy in patients with solid tumors
86. A phase II study of autologous irradiated tumor cells plus BCG in patients with metastatic malignant melanoma
87. Treatment of metastatic melanoma with an autologous tumor cell vaccine: Clinical and immunological results in 64 patients
88. Idiotype/granulocyte-macrophage colony stimulating factor fusion protein as a vaccine for B-cell lymphoma
89. Recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF) and autologous melanoma vaccine mediate tumor regression in patients with metastatic melanoma
90. Treatment of human melanoma with hapten-modified autologous vaccine
91. Autologous, hapten-modified vaccine as a treatment for human cancers
92. Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases
93. Overview of melanoma vaccines: Active specific immunotherapy for melanoma patients
94. Protective antitumor immunity induced by immunization with completely allogeneic tumor cells
95. Allogeneic murine melanoma cell vaccine; a model for the development of human allogeneic cancer vaccine
96. Preliminary results of a randomized trial of adjuvant immunotherapy in patients with malignant melanoma who have lymph node metastases
97. Identification of a human neuroectodermal tumor antigen (OFA-I-2) as ganglioside CD2
98. Ganglioside GM2 as a human tumor antigen (OFA-I-1)
99. Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients
100. A monoclonal antibody recognizes an O-acetylated sialic acid in a human melanoma-associated ganglioside
101. An epitope common to gangliosides O-acetyl-GD3 and GD3 recognized by antibodies in melanoma patients after active specific immunotherapy
102. Immunochemical characterization of fetal antigen isolated from spent medium of a human melanoma cell line
103. Induction of antibody to a tumor-associated antigen by immunization with a whole melanoma cell vaccine
104. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma
105. Melanoma patients immunized with melanoma ceil vaccine induce antibody responses to recombinant MAGE-1 antigen
106. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas
107. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes
108. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression
109. The melanoma antigen gp75 is the human homologue of the mouse b (brown) locus gene product
110. Vaccine therapy for malignant melanoma
111. Improved survival of advanced stage IV melanoma following active immunotherapy: Correlation with immune responses to melanoma vaccine
112. Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine
113. Polyvalent melanoma cell vaccine induced delayed type hypersensitivity and in vitro cellar immune response
114. Attempts to optimize specific immunotherapy for melanoma
115. Active specific immunotherapy of melanoma with allogeneic ceil lysates: Rationale, results and possible mechanisms of action
116. Perspective on allogeneic melanoma lysates in active specific immunotherapy
117. A new approach in specific, active immunotherapy
118. A new approach in the immunotherapy of carcinoma of colon and rectum
119. A southeastern cancer study group phase I/II trial with vaccina melanoma oncolysates
120. A phase I/II SECSG (Southeastern cancer study group) pilot study of surgical adjuvant immunotherapy with vaccinia melanoma oncolysates (VMO)
121. Active specific immunotherapy with vaccinia melanoma oncolysate
122. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: The final analysis of data from a phase III, randomized, double blind multicenter vaccinia melanoma oncolysate trial
123. Active immunotherapy with viral lysates of micrometastases following surgical removal of high risk melanoma
124. Relationship between immune response to melanoma vaccine and clinical outcome in stage II malignant melanoma
125. Improved survival of patients with melanoma with an antibody response to immunization to a polyvalent melanoma vaccine
126. Phase 3, double blind, trial of a shed polyvalent, melanoma vaccine in stage III melanoma
127. Specific active immunotherapy of cancer using genetically modified tumor vaccines
128. Characterization of human tumor cell lines with the cDNA encoding either tumor necrosis factor-a (TNF-A) or interleukin-2 (IL-2)
129. CD80 expression in an HLA-A2 positive human non-small ceil lung cancer cell line enhances proliferation and cytotoxicity of-A2 positive T-cells derived from normal donors and patients with non-small cell lung cancer
130. Costimulation of T-cells for tumor immunity
131. Tumor immunogenicity determines the effect of B7 costimulation on T-cell mediated tumor immunity
132. + T-cells by B7-transfected melanoma cells
133. Generation of primary tumor specific cytotoxic lymphocytes from autoiogous and human lymphocyte antigen class I matched allogeneic peripheral blood lymphocytes by B7 gene modified melanoma cells
134. High efficiency gene transfer into primary human tumor explants without cell selection
135. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response
136. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity
137. Immunization with a syngeneic tumor infected with recombinant vaccinia virus expressing granulocyte-macrophage colony-stimulating factor (GM-CSF) induces tumor regression and long-lasting systemic immunity
138. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma
139. Identification of specific cytolytic immune responses against autologous tumor in human bearing malignant melanoma
140. Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas: Activation by interleukin-2 and autologous tumor cells, and involvement of the T cell receptor
141. Human tumor-infiltrating lymphocytes. Analysis of lymphokine mRNA expression and relevance to cancer immunotherapy
142. Cell transfer therapy: Clinical applications
143. Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report
144. Treatment of patients with metastatic melanoma autologous tumor-infiltrating lymphocytes and interleukin-2
145. Identification of the immunodoniinant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2 restricted tumor infiltrating lymphocytes
146. Recognition of multiple epitopes in the human melanoma antigen gp100 associated with in vivo tumor regression
147. Identification of a novel peptide derived from the melanocyte-specific gp100 antigen as the dominant epitope recognized by an HLA-A2.1-restricted anti-melanoma CTL line
148. Identification of a human melanoma antigen recognized by tumor infiltrating lymphocytes associated with in vivo tumor rejection
149. + cytotoxic T lymphocytes
150. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T-lymphocytes on HLA-A2 melanomas
151. A non-apeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T-lymphocytes directed against tumor antigen-MZ2-E
152. BAGE: A new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes
153. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma
154. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocytes lines
155. Tumor specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer
156. Occasional memory CTL responses of patients with human papillomavirus type 16 positive cervical lesions against a human leukocyte antigen A*0201 restricted E7 encoded epitope
157. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine
158. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer
159. Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, an oncogenic self-protein
160. Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins
161. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells
162. Definition of specific peptide motifs for four major HLA-A alleles
163. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection
164. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumor immunity
165. Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity
166. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cell, B7 co-stimulation, and T helper cell 1-associated cytokines
167. Induction of antitumor immunity using bone-marrow generated dendritic cells
168. Tumor regression responses in melanoma patients treated with a peptide encoded by the gene MAGE-3
169. Improved induction of melanoma reactive CTL with peptides from melanoma antigen gpl00 modified at HLA-A*0201 binding residues
170. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen-presenting cells
171. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
172. Human immunity against a tandem repeat epitope of human mucin MUG-1 in sera from breast, pancreatic and colon cancer patients
173. Production of MUC1 and MUC2 mucins by human tumor cell lines
174. Expression of MUC1, MUC2, MUC3 and MUC4 mucin mRNAs in human pancreatic and intestinal tumor cell lines
175. Vaccination against tumor cells expressing breast cancer epithelial tumor antigen
176. Structure and biology of a carcinoma-associated mucin, MUC1
177. A short sequence, within the amino acid tandem repeat of a cancer-associated mucin, contains immunodominant epitopes
178. Biophysical characterization of one-, two-, and three-tandem repeats of human mucin (muc-1) protein core
179. Tumor selective reactivity of a monoclonal antibody prepared against a recombinant peptide derived from the DF3 human breast carcinoma-associated antigen
180. Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC1 mucin gene: Effect of immunization on the growth of murine mammary adenocarcinoma cells transfected with the human MUC1 gene
181. Specific MHC-unrestricted recognition of tumor associated mucins by human cytotoxic T cells
182. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells
183. A phase I trial of a synthetic mucin peptide vaccine: Induction of specific immune reactivity in patients with adenocarcinoma
184. Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin
185. MUC1 cross-reactive Galα(1,3)Gal antibodies in humans switch immune responses from cellular to humoral
186. Stuck in the MUC on the long and winding road: Antibodies that cross react with the tumor antigen MUC1 switch a cellular immune response to a humoral one with implications for the immunotherapy of cancer
187. Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-3 peptide loaded antigen presenting cell-based vaccine
188. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1
189. Immunotherapy of patients with melanoma based on the genes encoding melanoma antigens
190. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
191. CD1-restricted T-cell recognition of microbial lipoglycan antigens
192. Structural requirements for glycolipid antigen recognition by CDlb-restricted T-cells
193. Recognition of carbohydrate by major histocompatibility complex class I-restricted, glycopeptide-specific cytotoxic T lymphocytes
194. + T cells
195. General carcinoma antoantigens
196. Monoclonal antibodies and synthetic tumor-associated glycoconjugates in the study of the expression of Thomsen-Friedenreich-like and Tn-like antigens on human cancers
197. Analysis of human tumor associated Thomsen-Friedenreich antigen
198. Tn, a carcinoma associated antigen, reacts with anti-Tn of normal human sera
199. Sialosyl-Tn. A novel mucin antigen associated with prognosis in colorectal cancer patients
200. Expression of Tn, sialosyl-Tn, and T antigens in human colon cancer
201. Active specific immunotherapy against adenocarcinomas
202. Immunogenicity of synthetic TF-KLH (keyhole limpet hemocyanin) and sTn-KLH conjugates in colorectal carcinoma patients
203. Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside
204. Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients
205. Improved survival in stage III melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccination with GM2 ganglioside
206. Serological responses patterns of melanoma patients immunized with a GM2 ganglioside vaccine
207. Phase I trial of immunological adjuvant QS-21 with a GM2 ganglioside-KLH conjugate vaccine in patients with malignant melanoma
208. Relapse-free and overall survival are significantly prolonged by high-dose IFN alpha2b (HDI) compared to vaccine GM2-KLH with QS21 (GMK, Progenics) for high-risk resected stage IIB-III melanoma: Results of the Intergroup phase III study E1694/ C503801
209. Induction of antibodies against CD3 ganglioside in melanoma patients with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21
210. The carcinoembryonic antigen gene family: Structure, expressions, and evolution
211. Sequence analysis of carcinoembryonic antigen: Identification of glycosylation sites and homology with the immunoglobulin super-gene family
212. Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule
213. Cell adhesion activity of non-specific cross-reacting antigen (NCA) and carcinoembryonic antigen (CEA) expressed on CHO cell surface: Homophilic and heterophilic adhesion
214. A recombinant vaccinia virus expressing human carcinoembryonic antigen (CEA)
215. Antitumor activity and immune response induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine
216. Immunogenicity and safety of a recombinant vaccinia virus vaccine expressing the carcinoembryonic antigen gene in a nonhuman primate
217. Generation of human cytotoxic T-cells specific for human carcinoembryonic antigen (CEA) epitopes from patients immunized with recombinant vaccinia-CEA (rV-CEA) vaccine
218. Improved immunotherapy of a recombinant carcinoembryonic antigen vaccinia vaccine when given in combination with interleukin-2
219. Immunune response to a carcinoembryonic antigen polynucleotide vaccine
220. Speculations on idiotypes and homobodies
221. Towards a network theory of the immune system
222. Human anti-idiotypic antibodies induced a humoral and cellular immune response against a colorectal carcinoma-associated antigen in patients
223. Immunomodulatory activity of monoclonal anti-idiotypic antibody to anti-colorectal carcinoma antibody CO17-1A in animals and patients
224. Antitumor immunune response and interleukin 2 production induced in colorectal cancer patients by immunization with human monoclonal anti-idiotypic antibody
225. Clinical outcome of colorectal cancer patients treated with human monoclonal anti-idiotypic antibody
226. Enhanced cell-mediated tumor killing in patients immunized with human monoclonal anti-idiotypic antibody 105AD7
227. Induction of cellular immune responses by a murine monoclonal anti-idiotypic antibody recognizing the 791Tgp72 antigen expressed on colorectal, gastric and ovarian human tumors
228. Murine monoclonal anti-idiotypic antibody as a potential network antigen for human carcinoembryonic antigen
229. Induction of antitumor immunity by an anti-idiotype antibody mimicking carcinoembryonic antigen
230. Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotype antibody vaccine
231. Clinical and immune responses in advanced colorectal cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen
232. Clinical and immune responses in surgically resected colorectal cancer (CRC) patients treated with an anti-idiotype (Id) monoclonal antibody that mimics carcinoembryonic antigen (CEA) with or without 5-fluorouracil
233. Molecular mimicry of carcinoembryonic antigen by peptides derived from the structure of an anti-idiotype antibody
234. Neonatal mouse immunity against group B streptococcal infection by maternal vaccination with recombinant anti-idiotypes
235. Idiotypic immunization induces immunity to mutated p53 and tumor rejection
236. Idiotype vaccines: Forgotten but not gone
237. Idiotype vaccines in the clinic
238. Active specific immunotherapy in patients with melanoma: A clinical trial with mouse anti-idiotype monoclonal anti-bodies elicited with syngeneic anti-high molecular-weight-melanoma-associated antigen monoclonal antibodies
239. Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: Modulation of the immunogenecity in patients with malignant melanoma
240. Immunization of melanoma patients with BEC-2 antidiotypic monoclonal antibody that mimics CD3 ganglioside: Enhanced immunogenecity when combined with adjuvant
241. Immunization of melanoma patients with BEC2-keyhole limpet hemocyanin plus BCG intradermally followed by intravenous booster immunizations with BEC2 to induce anti-CD3 ganglioside anti-bodies
242. Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside CD2
243. Bone-marrow derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic antitumor immunity
244. Induction of antitumor immunity using bone-marrow generated dendritic cells
245. Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor immunity
246. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo
247. Antigen presenting cells pulsed with unfractionated tumor-derived peptides are potent tumor vaccines
248. Regression of tumors in mice vaccinated with professional antigen presenting cells pulsed with tumor extracts
249. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells